Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: Implication for gene therapy of radioresistant cancer

Gene Therapy

Volumn 4, Issue 12, 1997, Pages 1289-1299

  Gokhale, P C ^a   Soldatenkov, V ^a   Wang, F H ^a   Rahman, A ^a   Dritschilo, A ^a   Kasid, U ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antisense oligonucleotide gene therapy; Cationic liposomes; Head and neck cancer; Radioresistance; raf

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CHOLESTEROL; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; LIPOSOME; PHOSPHATIDYLCHOLINE; RAF PROTEIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENCAPSULATION; GENE THERAPY; HUMAN; HUMAN CELL; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY;

ANIMALIA;

EID: 0031450606     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300543     Document Type: Article

References (44)

1. Zamecnik PC, Goodchild J, Taguchi Y, Sarin PS. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci USA 1986; 83, 4143-4146.
2. Akhtar S, Agarwal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 1997; 18: 12-18.
3. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. New Engl J Med 1996; 334: 316-318.
4. Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 1986; 13: 97-102.
5. Agarwal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides Clin Pharmacokinet 1995; 28: 7-16.
6. Crook ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 1992; 32: 329-376.
7. Agarwal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 1996; 14: 376-387.
8. Altmarm K-H et al. Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia 1996; 50: 168-176.
9. Agarwal S et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA 1997; 94: 2620-2625.
10. Rahman A, White G, More N, Schein PS. Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1985; 45: 796-803
11. Feigner PL et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7417.
12. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179: 280-285.
13. Stewart MJ et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther 1992; 3: 267-275
14. Rahman A et al. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst. 1992; 84: 1909-1915.
15. Caplen NJ et al. In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE. Gene Therapy 1995; 2: 603-613.
16. Gokhale PC et al. An unproved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. Br J Cancer 1996; 74: 43-48.
17. Liu Y et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nature Biotechnol 1997; 15: 167-173.
18. Bennett CF et al. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992; 41: 1023-1033.
19. Litzinger DC et al. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochem Biophys Acta 1996; 1281: 139-149.
20. Leevers SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994; 369: 411-414.
21. Kasid U et al. Activation of Raf by ionizing radiation. Nature 1996; 382: 813-816.
22. Devary Y, Gottlieb RA, Smeal T, Karin M. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 1992; 71: 1081-1091.
23. Wang H-G, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638.
24. Zhang Y et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 1997; 89: 63-72
25. Patel BKR, Ray S, Whiteside TL, Kasid U. Correlation of constitutive activation of Raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells. Mol Catcinogen 1997; 18: 1-6.
26. Suy S et al. Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. Oncogene 1997, 14: 53-61.
27. Kasid U et al. Effect of antisense c-raf-l on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 1989; 243: 1354-1356.
28. Kasid U, Olah Z, Anderson W, Dritschilo A. Inhibition of c-RAF-1 protein kinase activity by antisense phosphorothioate oligonucleotides in human radiation resistant squamous carcinoma cells. Proc Int Congr Radiat Res 1991; P16-03: 242.
29. Kasid U, Pirollo K, Dritschilo A, Chang E. Oncogenic basis of radiation resistance. Adv Cancer Res 1993; 61: 195-233.
30. Monia BP et al. Antitumor activity of a phosphorothioate anti-sense oligonucleotide targeted against c-raf kinase. Nature Med 1996; 2: 668-675.
31. Soldatenkov VA et al. Inhibition of Raf-1 protein kinase by anti-sense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Cancer J Sci Am 1997; 3: 13-20.
32. Dent P et al. Reversal of Raf-1 activation by purified and membrane-associated protein phosphatases. Science 1995; 268: 1902-1906.
33. Fertil B, Deschavanne PJ, Lachet B, Malaise EP. In vitro radiosensitivity of six human cell lines: a comparative study with different statistical models. Radiat Res 1980; 82: 297-307.
34. Withers HR. Biologic basis of radiation therapy. In: Perez CA, Brady LW (eds). Principles and Practice of Radiation Oncology Lippincott: Philadelphia, 1987, pp 67-98.
35. Hall EJ. Radiobiology for the Radiologist. Lippincott, Philadelphia, 1988.
36. Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: a useful concept for interpretation of human cell survival curves. Radiat Res 1984; 99: 73-84
37. Mayhew E, Rustum YM, Szoka FC, Papahadjopoulos D. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes. Cancer Treat Rep 1979; 63: 1923-1928.
38. Sternberg B, Sorgi FL, Huang L. New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy. FEBS Lett 1994; 356: 361-366.
39. Gershon H, Ghirlando R, Guttsman SB, Minsky A Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. Biochemistry 1993; 32: 7143-7151
40. Sands H et al. Biodistribution and metabolism of internally H-labeled oligonucleotides. II. 3′,5′-blocked oligonucleotides. Mol Pharmacol 1995; 47: 636-646.
41. Hwang KJ. Liposome pharmacokinetics. In: Ostro MJ (ed). Liposomes - From Biophysics to Therapeutics. Marcel Dekker: New York, 1987, pp 109-155.
42. Zelphati O, Szoka FC. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 1996; 13: 1367-1372.
43. Weichselbaum RR et al. Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci USA 1986; 83: 2684-2688.
44. Albright N. Computer programs for the analysis of cellular survival data. Radiat Res 1987; 112: 331-340.